A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-21. Anything still debated is marked as such rather than presented as settled.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
== Research == Immunomodulating substances, such as drugs that prevent acetylcholine receptor modulation by the immune system, are currently being researched. Some research recently has been on anti-c5 inhibitors for treatment research as they are safe and used in the treatment of other diseases. Ephedrine seems to benefit some people more than other medications, but it has not been properly studied as of 2014. In the laboratory, MG is mostly studied in model organisms, such as rodents. In addition, in 2015, scientists developed an in vitro functional, all-human, neuromuscular junction assay from human embryonic stem cells and somatic-muscle stem cells. After the addition of pathogenic antibodies against the acetylcholine receptor and activation of the complement system, the neuromuscular co-culture shows symptoms such as weaker muscle contractions. Recent years, scientists have been working on finding the reliable biomarkers for MG to monitor the disease development and assess the severity.
1993/150) Council Tax (Liability for Owners) (Amendment) Regulations 1993 (S.I. 1993/151) Genetically Modified Organisms (Deliberate Release) Regulationa 1993 (S.I. 1993/152) Barnsley Community and Priority Services National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/153) Mersey Regional Ambulance Service National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/154) North Mersey Community National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/155) Shropshire's Mental Health National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/156) Thameside Community Health Care National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/157) Drivers' Hours (Passenger and Goods Vehicles) (Exemption) (Revocation) Regulations 1993 (S.I. 1993/158) Manchester Central Hospitals and Community Care National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/159) A30 and A39 Trunk Roads (Indian Queens, Fraddon and St Columb Road Bypasses and Slip Roads) Order 1993 (S.I. 1993/163) A30 and A39 Trunk Roads (Indian Queens, Fraddon and St Columb Road Bypasses) (Detrunking) Order 1993 (S.I. 1993/164) General Drainage Charges (Relevant Quotient) Regulations 1993 (S.I. 1993/165) Central Rating Lists (Amendment) Regulations 1993 (S.I. 1993/166) Spring Traps Approval (Scotland) Variation Order 1993 (S.I. 1993/167) Humberside and South Yorkshire (County Boundaries) Order 1993 (S.I. 1993/168) Special Road Schemes and Highways Orders (Procedure) Regulations 1993 (S.I.
The energy levels of a single particle in a quantum dot can be predicted using the particle in a box model in which the energies of states depend on the length of the box. For an exciton inside a quantum dot, there is also the Coulomb interaction between the negatively charged electron and the positively charged hole. By comparing the quantum dot's size to the exciton Bohr radius, three regimes can be defined. In the 'strong confinement regime', the quantum dot's radius is much smaller than the exciton Bohr radius, respectively the confinement energy dominates over the Coulomb interaction. In the 'weak confinement' regime, the quantum dot is larger than the exciton Bohr radius, respectively the confinement energy is smaller than the Coulomb interactions between electron and hole. The regime where the exciton Bohr radius and confinement potential are comparable is called the 'intermediate confinement regime'.
=== Names === The natural product was named cyclosporin by the German-speaking scientists who first isolated it and cyclosporine when translated into English. Per International Nonproprietary Name (INN) guidelines for drugs, the y was replaced with i so that the INN for the medication is spelled ciclosporin. Ciclosporin is the INN and the British Approved Name (BAN), while cyclosporine is the United States Adopted Name (USAN) and cyclosporin is a former BAN.
Acute intermittent porphyria Adrenoleukodystrophy (Schilder's disease) Alkaptonuria Aminolevulinic acid dehydratase deficiency porphyria (Doss porphyria, plumboporphyria) B-mannosidase deficiency Carotenosis Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy syndrome (CADASIL syndrome) Cerebrotendinous xanthomatosis Citrullinemia Congenital erythropoietic porphyria (Gunther's disease) Diabetic bulla (bullosis diabeticorum, bullous eruption of diabetes mellitus) Diabetic cheiroarthropathy Diabetic dermopathy (shin spots) Dystrophic calcinosis cutis Eruptive xanthoma Erythropoietic protoporphyria Fabry disease (Anderson–Fabry disease, angiokeratoma corporis diffusum) Familial alpha-lipoprotein deficiency (Tangier disease) Familial amyloid polyneuropathy Familial apoprotein CII deficiency Familial combined hyperlipidemia (multiple-type hyperlipoproteinemia) Familial defective apolipoprotein B-100 Familial dysbetalipoproteinemia (broad beta disease, remnant removal disease) Familial hypertriglyceridemia Farber disease (fibrocytic dysmucopolysaccharidosis, lipogranulomatosis) Fucosidosis Gaucher's disease Gout (podagra, urate crystal arthropathy, urate deposition disease) Hartnup disease (pellagra-like dermatosis) Hemodialysis-associated amyloidosis Hepatoerythropoietic porphyria Hereditary coproporphyria Hereditary gelsolin amyloidosis Heredofamilial amyloidosis Hunter syndrome Hurler syndrome (gargoylism, mucopolysaccharidosis type I) Hurler–Scheie syndrome (mucopolysaccharidosis type I H-S) Hyaluronidase deficiency (mucopolysaccharidosis type IX) Iatrogenic calcinosis cutis Idiopathic scrotal calcinosis (idiopathic calcified nodules of the scrotum) Lafora disease Lesch–Nyhan syndrome (juvenile gout) Lichen amyloidosis Limited joint mobility Lipoid proteinosis (hyalinosis cutis et mucosae, Urbach–Wiethe disease) Lipoprotein lipase deficiency (chylomicronemia, chylomicronemia syndrome) Macular amyloidosis Maroteaux–Lamy syndrome (mucopolysaccharidosis type VI) Medication-induced hyperlipoproteinemia Metastatic calcinosis cutis Milia-like calcinosis Morquio's disease (mucopolysaccharidosis type IV) Necrobiosis lipoidica (necrobiosis lipoidica diabeticorum) Niemann–Pick disease Nodular amyloidosis Nodular xanthoma Normolipoproteinemic xanthomatosis Obstructive liver disease (xanthomatous biliary cirrhosis) Ochronosis Osteoma cutis Palmar xanthoma Phenylketonuria Phytosterolemia (sitosterolemia) Porphyria cutanea tarda Primary cutaneous amyloidosis Primary systemic amyloidosis Prolidase deficiency Pseudoporphyria (pseudoporphyria cutanea tarda) Sanfilippo syndrome Scheie syndrome (mucopolysaccharidosis type I S) Secondary cutaneous amyloidosis Secondary systemic amyloidosis Sialidosis Sly syndrome (mucopolysaccharidosis type VII) Subepidermal calcified nodule (solitary congenital nodular calcification, Winer's nodular calcinosis) Transient erythroporphyria of infancy (purpuric phototherapy-induced eruption) Traumatic calcinosis cutis Tuberoeruptive xanthoma (tuberous xanthoma) Tumoral calcinosis Variegate porphyria (mixed hepatic porphyria, mixed porphyria, South African genetic porphyria, South African porphyria) Verruciform xanthoma Waxy skin Wilson's disease (hepatolenticular degeneration) Xanthelasma palpebrarum (xanthelasma) Xanthoma diabeticorum Xanthoma planum (plane xanthoma) Xanthoma striatum palmare Xanthoma tendinosum (tendinous xanthoma) Xanthoma tuberosum
Sources: en.wikipedia.org
The reference values vary across studies, ranging from > 25 cm/s to > 35 cm/s. Values above 35 cm/s indicate the absence of arterial disease, values below 25 cm/s indicate arterial insufficiency, and values of 25–35 cm/s are indeterminate because they are less specific (see image below). The data obtained should be correlated with the degree of erection observed. If the peak systolic velocities are normal, the final diastolic velocities should be evaluated, those above 5 cm/s being associated with venogenic ED.
Leucine-rich repeats and death domain containing, also known as LRDD or p53-induced protein with a death domain (PIDD), is a protein which in humans is encoded by the LRDD gene. The leucine-rich repeat (LRR), first identified by Patthy, is a domain involved in protein-protein interactions and is present in numerous proteins that serve a variety of cellular roles. Leucine-rich repeats (LRR) proteins in eukaryotic cells are found in the nucleus, cytoplasm, extracellular matrix and plasma membrane.
Testing for the presence of residual solvents in Active Pharmaceutical Ingredients (APIs) is critical for patient safety and commonly follows United States Pharmacopeia (USP) Method <467> guidelines, or more broadly, International Council for Harmonisation (ICH) Guideline Q3C(R6). The gas chromatography (GC) runtime suggested by USP Method 467 is approximately 60 min. A generic method for residual solvent analysis by GC-MS describes conditions that include a runtime of approximately 30 minutes. A GC-VUV and static headspace method was developed using a chromatographic compression strategy that resulted in a GC runtime of 8 minutes. The GC-VUV method uses a flow rate of 4 mL/min and an oven ramp of 35 °C (held for 1 min), followed by an increase to 245 °C at a rate of 30 °C/min. Figure 5 compares the results when the general conditions of the GC-MS method were followed against the GC-VUV method run with Class 2 residual solvents. Tetralin eluted at approximately 35 minutes using the GC-MS method conditions, whereas the analyte had a retention time of less than 7 minutes when the GC-VUV method was applied. The co-elution of m- and p-xylene occurred in both GC-MS and GC-VUV method runs. VUV software matched the analyte absorbance of both isomers with VUV library spectra (Figure 2) to deconvolve the overlapping signals as displayed in Figure 6. Goodness of fit information ensures that the correct compound assignment takes place during the post-run data analysis.
Christianity and Druze are Abrahamic religions that share a historical traditional connection with some major theological differences. The two faiths share a common place of origin in the Middle East and are both monotheistic. Christian and Druze communities share a long history of interaction dating back roughly a millennium, particularly in Mount Lebanon. Over the centuries, they have interacted and lived together peacefully, sharing common social and cultural landscapes, despite occasional exceptions. Moreover, Druze beliefs, scriptures and teachings incorporate several elements from Christianity. Historically, the relationship between the Druze and Christians has been characterized by harmony and peaceful coexistence. The divisions within society mainly ran along the lines of class distinction between elites and commoners (alahi) instead of along religious divides in places like Mount Lebanon. Amicable relations between the two groups prevailed throughout history, with the exception of some periods, including 1860 Mount Lebanon civil war. In the Levant region, the conversion of Druze to Christianity was a common practice. Throughout history, there have been instances where prominent members of the Druze community, including some of Shihab dynasty members, as well as the Abi-Lamma clan, embraced Christianity. Bashir Shahib II even presented himself as Druze to Druze populations and as Christian to Christian populations.
Sources: en.wikipedia.org
The two substrates of this enzyme are L-α-glycerophosphoric acid, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are dihydroxyacetonephosphoric acid, reduced NADH, and a proton. The enzyme can also use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is sn-glycerol-3-phosphate:NAD(P)+ 2-oxidoreductase. Other names in common use include L-glycerol-3-phosphate:NAD(P)+ oxidoreductase, glycerol phosphate dehydrogenase (nicotinamide adenine dinucleotide, (phosphate)), glycerol 3-phosphate dehydrogenase (NADP+), and glycerol-3-phosphate dehydrogenase [NAD(P)+]. This enzyme participates in glycerophospholipid metabolism.
The failure of the January Uprising in Poland caused a major psychological trauma and became a historic watershed; indeed, it sparked the development of modern Polish nationalism. The Poles, subjected within the territories under the Russian and Prussian administrations to still stricter controls and increased persecution, sought to preserve their identity in non-violent ways. After the uprising, Congress Poland was downgraded in official usage from the "Kingdom of Poland" to the "Vistula Land" and was more fully integrated into Russia proper, but not entirely obliterated. The Russian and German languages were imposed in all public communication, and the Catholic Church was not spared from severe repression. Public education was increasingly subjected to Russification and Germanisation measures. Illiteracy was reduced, most effectively in the Prussian partition, but education in the Polish language was preserved mostly through unofficial efforts. The Prussian government pursued German colonization, including the purchase of Polish-owned land. On the other hand, the region of Galicia (western Ukraine and southern Poland) experienced a gradual relaxation of authoritarian policies and even a Polish cultural revival. Economically and socially backward, it was under the milder rule of the Austro-Hungarian Monarchy and from 1867 was increasingly allowed limited autonomy. Stańczycy, a conservative Polish pro-Austrian faction led by great land owners, dominated the Galician government. The Polish Academy of Learning (an academy of sciences) was founded in Kraków in 1872.
An even better isolation of veratridine from veratrine is achieved using high-performance liquid chromatography (HPLC); as commercially available veratridine may vary in purity, HPLC purification of veratrine is a preferred method for isolation of veratridine for biological studies.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.